Wanderley, Carlos Wagner de Souza 
; Correa, Tatiana Strava; Scaranti, Mariana; Cunha, Fernando de Queiroz ; Barroso-Sousa, Romualdo
Source: Frontiers in Immunology. Unidade: FMRP
Subjects: REPARAÇÃO DE DNA, IMUNOTERAPIA, NEOPLASIAS, FARMACOTERAPIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
WANDERLEY, Carlos Wagner de Souza et al. Targeting PARP1 to enhance anticancer checkpoint immunotherapy response: rationale and clinical implications. Frontiers in Immunology, v. 13, p. 1-10, 2022Tradução . . Disponível em: https://doi.org/10.3389/fimmu.2022.816642. Acesso em: 12 nov. 2024.APA
Wanderley, C. W. de S., Correa, T. S., Scaranti, M., Cunha, F. de Q., & Barroso-Sousa, R. (2022). Targeting PARP1 to enhance anticancer checkpoint immunotherapy response: rationale and clinical implications. Frontiers in Immunology, 13, 1-10. doi:10.3389/fimmu.2022.816642NLM
Wanderley CW de S, Correa TS, Scaranti M, Cunha F de Q, Barroso-Sousa R. Targeting PARP1 to enhance anticancer checkpoint immunotherapy response: rationale and clinical implications [Internet]. Frontiers in Immunology. 2022 ; 13 1-10.[citado 2024 nov. 12 ] Available from: https://doi.org/10.3389/fimmu.2022.816642Vancouver
Wanderley CW de S, Correa TS, Scaranti M, Cunha F de Q, Barroso-Sousa R. Targeting PARP1 to enhance anticancer checkpoint immunotherapy response: rationale and clinical implications [Internet]. Frontiers in Immunology. 2022 ; 13 1-10.[citado 2024 nov. 12 ] Available from: https://doi.org/10.3389/fimmu.2022.816642
